Contrast agents are routinely used in MRI to detect and evaluate tissue lesions. Conventional clinical protocols use T1-weighted sequences to visualize Gd contrast agent enhancement. Because T1-weighted MRI does not produce quantitative measurements, it is difficult to describe the lesion enhancement in quantitative terms and to infer the degree of the underlining disease activities of the lesions. A fast, whole-brain high-resolution T1 mapping method was developed to address this problem and applied to multiple sclerosis.
This abstract and the presentation materials are available to members only; a login is required.